AKT1 and osteosarcoma: Furthermore, we demonstrated that MK2206 as a AKT inhibitor can significantly inhibit the stemness of osteosarcoma cells, and combined cisplatin therapy has shown synergistic inhibition effect in vitro and in vivo.